Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic AZN
Time: 16:35:03
Mid Price: 2910.50
Change Today: 15.00 Ascending
Change % Today: 0.52 Ascending
Fifty Two Week High: 3102.50
Fifty Two Week Low: 2255.00
Market Capital: 42258.77
Period & price data
Period Price
Now: 2910.50
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
Epic: AZN
News: Latest news
Web Site: AstraZeneca
Other Articles: 23-02-201016-02-201009-02-2010

AstraZeneca

AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.

Sales in 2007 totalled $29.6 billion, with an operating profit of $9 billion

Tuesday, February 09, 2010

AstraZeneca’s CRESTOR gets FDA approval for use in stroke and heart disease prevention

company news image

AstraZeneca (LSE: AZN) said its CRESTOR treatment has been approved for a new indication by the US Food and Drug Administration (FDA), for use in reducing the risk of stroke, heart attack and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD).

The FDA approval was based on data from the landmark JUPITER study which evaluated the impact of CRESTOR 20 mg on reducing major cardiovascular (CV) events in a previously unstudied population.

"Not only is this approval a significant milestone for AstraZeneca, but it is also important for the patients who could now benefit from CRESTOR therapy under this approved indication", AstraZeneca chief medical officer Howard Hutchinson commented, “This new indication adds to the significant body of evidence physicians use to evaluate CRESTOR as a treatment option".

CRESTOR (rosuvastatin calcium) is indicated an adjunct to diet to reduce elevated bad cholesterol levels and to inclease levels of good cholesterol in patients with primary hyperlipidemia and mixed dyslipidemia. CRESTOR is also indicated as an adjunct to diet to slow the progression of atherosclerosis in adult patients.

JUPITER stands for ‘Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin’. The study evaluated the effect CRESTOR (rosuvastatin calcium) had on the occurrence of major cardiovascular (CV) disease events in 17,802 people, consisting of men over fifty and women over sixty.

AstraZeneca said that in the JUPITER study, CRESTOR significantly reduced the relative risk of heart attack by 54%, stroke by 48%, and arterial revascularization by 46%.

The JUPITER study is a part of the company’s GALAXY clinical trials programme, which are designed to address important unanswered questions in statin research, AstraZeneca said. Currently, more than 65,000 patients have been recruited from 55 countries worldwide to participate in the GALAXY Programme.

NewsNow icon AddThis Feed Button
Register here to be notified of future AstraZeneca articles.

Other AstraZeneca articles

More articles ►

Other AstraZeneca news

More news ►

Investors interested in AstraZeneca recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.